Thank you for your questions. The main condition for starting Vedolizumab or Ustekinumab was failure of anti-TNF treatment, so there was no age limit. Our youngest patients were 4 years old.
10/27 children failed Vedolizumab or Ustekinumab. Out of these 10 patients, 5 patients were primary nonresponders, while the other 5 had secondary loss of response.
Please let me know if you have more questions. I would be more than happy to respond.
Dear Rajiv,
Thank you for your questions. The main condition for starting Vedolizumab or Ustekinumab was failure of anti-TNF treatment, so there was no age limit. Our youngest patients were 4 years old.
10/27 children failed Vedolizumab or Ustekinumab. Out of these 10 patients, 5 patients were primary nonresponders, while the other 5 had secondary loss of response.
Please let me know if you have more questions. I would be more than happy to respond.
Thanks Roxana